Description

Ingelvac PRRS ATP is a contemporary PRRS vaccine manufactured through the attenuation of a recently isolated atypical PRRS parent strain.

Features

- Developed from a newly isolated atypical PRRS parent strain.

- Reduces PRRS viremia in challenged animals.

- Demonstrated 120-day duration of immunity (DOI).

- Enhanced safety profile – demonstrated lack of reversion to virulence in five back passage study.

Benefits

Ingelvac PRRS ATP vaccinates had higher post-challenge weight gains than nonvaccinated challenged controls.

Demonstrated protection following respiratory challenge with an extremely virulent heterologous atypical PRRS virus.

No leukopenia.

Reduced lung lesions.

Advantages

Ingelvac PRRS ATP is a highly effective modified live PRRS vaccine, with demonstrated protection against newer more highly virulent heterologous strains of atypical PRRS virus.

Dosage & Administration

Rehydrate the vaccine by adding the full contents of the accompanying liquid diluent to the vaccine vial. Shake well and use immediately. Rehydrate only with the diluent provided: do not mix with other materials.

Using aseptic technique, administer a single 2 mL dose intramuscularly to swine 3 weeks of age or older, up to 18 weeks of age. Administer the complete 2 mL dose to each pig vaccinated. Efficacy and safety of the vaccine at other than the dose or route prescribed on the label is unknown and therefore, not recommended and not USDA approved. Anaphylactoid reactions may occur.

Antidote: Epinephrine

Precautions

For veterinary use only, for use only in swine in PRRS virus positive herds as directed.

Uses

Recommended for the vaccination of healthy, susceptible swine 3 weeks of age or older, up to 18 weeks of age, as an aid in the reduction of disease associated with atypical Porcine Reproductive and Respiratory Syndrome virus, respiratory form. The duration of immunity is throughout the finishing period, or up to 4 months postvaccination.

Recommended for use in healthy, susceptible swine in PRRS virus positive herds only, per label directions.

Vaccination of Breeding Animals:
Do not vaccinate adult sows, gilts or boars.
Do not vaccinate pregnant sows.

Highlights

- Significantly reduced incidence of elevated rectal temperatures.

- Significantly reduced viral induced lung lesions.

- Weight gain performance was significantly better in the Ingelvac PRRS ATP groups as compared to nonvaccinated/challenged groups.

- Significantly reduced symptoms of respiratory disease caused by atypical PRRS virus.

- Significantly reduced leukopenia.

Packaging Options (top)

Contact Information For INGELVAC® PRRS ATP (top)

Boehringer Ingelheim Vetmedica, Inc.
2621 North Belt Highway
St. Joseph, MO 64506
800-821-7467 Information
800-325-9167 Sales
816-236-2717
email: tluther@bi-vetmedica.com
internet: http://www.bi-vetmedica.com

General Product Information Documents (top)

Product Image for INGELVAC® PRRS ATP (top)

Related Technical Bulletins (top)

Related Marketing Documents (top)